Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is
notoriously resistant to immunotherapy mainly due to its unique immune microenvironment …

Biomarker discovery and development are popular for detecting the subtle diseases.
However, biomarkers are needed to be validated and approved, and even fewer are ever …

Nearly two-thirds of cancer patients are treated with radiation therapy (RT), often with the
intent to achieve complete and permanent tumor regression (local control). RT is the primary …

Recent efforts in brain tumor research have been directed towards the modulation of the
immune system for therapeutic interventions. Several human cancers, including gliomas, are …

Glioma is the most common primary intracranial tumor and has the greatest prevalence of all
brain tumors. Treatment resistance and tumor recurrence in GBM are mostly explained by …

Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an
immunosuppressive microenvironment. Different factors shaping this tumor …

Acrolein, which is the most reactive aldehyde, is a byproduct of lipid peroxidation in a
hypoxic environment. Acrolein has been shown to form acrolein-cysteine bonds, resulting in …

Background Gliomas are the most common and aggressive tumors of the central nervous
system. A robust and widely used blood-based biomarker for glioma has not yet been …

Spontaneous venous thrombosis is often the first clinical sign of cancer, and it is linked to a
worsened survival rate. Traditionally, tumor-cell induced platelet activation has been the …

Background Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has
a limited number of prognostic factors. Inflammation has been demonstrated to play a key …